Ibogaine FAQ — Frequently Asked Questions

Question 1

Is Ibogaine safe?

Accepted Answer

Ibogaine carries significant medical risks and is not safe for all individuals. It can cause life-threatening cardiac arrhythmias, particularly in people with pre-existing heart conditions or those taking contraindicated medications. When administered in a medically supervised setting with thorough pre-treatment screening, risks are substantially reduced but never eliminated. Cardiac screening and medical supervision are considered minimum standards of care. Always consult a licensed physician before considering ibogaine treatment.

Question 2

Is Ibogaine legal in the United States?

Accepted Answer

Ibogaine is a Schedule I controlled substance in the United States, making it federally illegal to manufacture, distribute, or possess. There are no FDA-approved ibogaine treatments. Americans seeking ibogaine treatment typically travel to legal jurisdictions such as Mexico, Portugal, or Brazil. Legislative momentum is growing, with Texas funding a $50 million clinical trial program, but no state has legalized ibogaine for therapeutic use as of 2025.

Question 3

What are the risks of Ibogaine?

Accepted Answer

The primary risks of ibogaine include cardiac arrhythmia (QT prolongation), severe nausea, ataxia, and an intense 18–36 hour psychedelic experience. Fatalities have occurred, most commonly in individuals with undetected cardiac conditions or those combining ibogaine with opioids or other contraindicated substances. Ibogaine inhibits hERG potassium channels, affecting heart rhythm for up to 72 hours post-administration. Psychological risks include re-traumatization and acute psychosis. These risks are substantially reduced with thorough medical screening and professional supervision, but are never fully eliminated.

Question 4

How long does an Ibogaine experience last?

Accepted Answer

A full ibogaine experience typically lasts 18 to 36 hours. The acute visionary phase lasts approximately 4–8 hours, followed by a prolonged reflective phase of 8–20 hours. Cardiac monitoring is required throughout. Residual effects including insomnia and sensory sensitivity can persist 24–72 hours after administration. Reputable treatment centers require a minimum of 24–48 hours of post-administration medical supervision. Total residential programs typically run 5–14 days including preparation and integration.

Question 5

What happens during an Ibogaine retreat?

Accepted Answer

An ibogaine retreat typically spans 5–14 days and includes three phases: pre-treatment preparation (medical screening, ECG, psychological assessment), the ibogaine session (18–36 hours under continuous cardiac monitoring), and post-treatment integration (therapy and counseling). Pre-treatment medication tapering may be required weeks in advance. Integration support — both on-site and after returning home — is considered essential for maintaining therapeutic outcomes. Facility quality varies widely; verifying staff credentials and emergency protocols is strongly recommended.

Question 6

Who should NOT consider Ibogaine?

Accepted Answer

Ibogaine is contraindicated for individuals with heart disease, arrhythmia, long QT syndrome, or a family history of sudden cardiac death. It is also contraindicated for those taking opioids (without supervised taper), SSRIs, SNRIs, stimulants, lithium, or QT-prolonging medications. Individuals with a history of psychosis, schizophrenia, or bipolar disorder with psychotic features should not use ibogaine. Pregnancy, severe liver or kidney disease, and active seizure disorder are additional contraindications. A complete physician review is mandatory before any ibogaine treatment.

Question 7

Does Ibogaine help with depression?

Accepted Answer

Preliminary research suggests ibogaine may have antidepressant properties, but it is not an approved treatment for depression. A 2023 observational study in Nature Medicine found significant reductions in depression and PTSD symptoms in veterans, but large randomized controlled trials are still pending. Ibogaine should not replace established, evidence-based depression treatments. Anyone experiencing depression should consult a licensed mental health professional before considering ibogaine.

Question 8

How much does an Ibogaine retreat cost?

Accepted Answer

Ibogaine treatment costs typically range from $3,500 to $20,000+ depending on location, program length, and level of medical supervision. Mexico is the most common destination for U.S. patients, with costs ranging $5,000–$15,000 for a full medical program. Health insurance does not cover ibogaine treatment. Financial assistance is available for veterans and first responders through programs like VETS grants and the Heroic Hearts Project.

Question 9

Is cardiac screening required before Ibogaine treatment?

Accepted Answer

Cardiac screening before ibogaine treatment is a medical necessity, not optional. The minimum required workup includes a 12-lead ECG with QTc measurement, serum electrolytes, and a complete cardiac history. Ibogaine prolongs the QT interval and can cause fatal arrhythmias in individuals with pre-existing cardiac conditions. Continuous ECG monitoring during the treatment session is considered a standard of care. Any facility not requiring cardiac screening should be avoided.

Question 10

What is the difference between Ibogaine and Ketamine?

Accepted Answer

Ibogaine and ketamine differ substantially in mechanism, duration, legal status, and risk profile. Ketamine is FDA-approved and legally available in the U.S.; ibogaine is Schedule I and requires international travel. Ibogaine lasts 18–36 hours vs. 45–90 minutes for ketamine. Ibogaine carries significant cardiac risk (QT prolongation); ketamine has low cardiac risk at therapeutic doses. Both require qualified medical supervision and should not be used as first-line treatments without consulting a licensed psychiatrist.

Question 11

Does Ibogaine work for opioid addiction?

Accepted Answer

Ibogaine has shown promise for interrupting opioid dependence, with studies reporting significant reductions in withdrawal symptoms and cravings. However, it is not an FDA-approved treatment for opioid use disorder and is not a cure for addiction. Relapse rates without follow-up integration support remain significant. Methadone must be tapered before treatment due to cardiac risk. Fentanyl use requires careful medical management. Integration support and behavioral therapy are essential for sustained recovery outcomes.

Question 12

Can Ibogaine help with PTSD?

Accepted Answer

Emerging research suggests ibogaine may reduce PTSD symptoms. A 2023 Nature Medicine observational study found significant reductions in PTSD symptom severity in military veterans at one-month follow-up. However, ibogaine is not an approved PTSD treatment, and findings require confirmation in randomized controlled trials. Risk of re-traumatization is real. Trauma-informed integration support is essential. Veterans may qualify for grant funding through programs like VETS and Heroic Hearts Project.

Question 13

Can Ibogaine help with traumatic brain injury (TBI)?

Accepted Answer

Preliminary research suggests ibogaine may support neurological recovery in TBI through promotion of neuroplasticity and neurotrophic factor expression. A 2023 Nature Medicine study found significant improvements in cognitive function and disability scores in veterans with TBI. However, ibogaine is not an approved TBI treatment. TBI may alter ibogaine's effects and risk profile, making neurological evaluation essential before considering treatment.

Question 14

What is integration therapy after Ibogaine?

Accepted Answer

Integration therapy is the psychological support process following an ibogaine experience, helping individuals process insights, difficult emotions, and translate the experience into lasting behavioral change. Most practitioners consider integration as important as the treatment itself. Integration typically continues for 3–6 months after treatment with a licensed therapist trained in psychedelic integration. Resources include ICEERS El Faro, Fireside Project, and Psychedelic Support Network.

Question 15

What is the legal status of Ibogaine worldwide?

Accepted Answer

Ibogaine's legal status varies by country. It is Schedule I (illegal) in the U.S., Class A (illegal) in the UK, and prohibited in Australia. It is unscheduled and legal in Mexico, legal by prescription in Brazil and Canada (Special Access Program), decriminalized in Portugal, and legally protected in Gabon. Mexico is the most common treatment destination for North American patients. Legal status can change; always verify current regulations before travel.

Question 16

What does the research say about Ibogaine?

Accepted Answer

Research on ibogaine is promising but limited to observational studies. Key findings include significant reductions in opioid withdrawal symptoms (Mash et al.), PTSD severity (2023 Nature Medicine veterans study), and depression scores. Large randomized controlled trials are underway, including a $50M UT Austin trial funded by the VETS Act. The research consensus identifies genuine therapeutic potential alongside significant cardiac risks requiring medical infrastructure.

Question 17

How do I find a reputable Ibogaine provider?

Accepted Answer

Finding a reputable ibogaine provider requires verifying: physician-led medical team, mandatory cardiac screening (ECG), continuous cardiac monitoring during treatment, verifiable staff credentials, and structured integration support. Key questions include: Is a physician present throughout treatment? What are your cardiac exclusion criteria? What are your emergency protocols? Resources for finding vetted providers include GITA (Global Ibogaine Therapy Alliance), ICEERS, and MAPS.

Question 18

What is the difference between Ibogaine and Ayahuasca?

Accepted Answer

Ibogaine and ayahuasca differ in origin, mechanism, duration, and risk profile. Ibogaine (from Central Africa) lasts 18–36 hours and carries significant cardiac risk (QT prolongation). Ayahuasca (from the Amazon) lasts 4–6 hours and carries lower cardiac risk but serious MAOI drug interaction risks. Ibogaine is primarily studied for addiction and PTSD; ayahuasca for depression and trauma. Both are legally complex in the U.S. and require qualified supervision.

Question 19

Are there Ibogaine programs specifically for veterans?

Accepted Answer

Several ibogaine treatment centers offer dedicated programs for veterans, often with grant funding available. The VETS Act (2022) directed $50M to UT Austin for clinical trials. Financial assistance is available through VETS grants, Heroic Hearts Project, and the 343 Fund. VA benefits do not cover ibogaine treatment. The 2023 Nature Medicine study showed 88% mean reduction in PTSD symptom severity in special operations veterans.

Question 20

What is the traditional and spiritual use of Ibogaine?

Accepted Answer

Ibogaine derives from the Tabernanthe iboga plant, used for centuries in the Bwiti spiritual tradition of Central Africa (primarily Gabon, Cameroon, Congo). Traditional use involves multi-day initiation ceremonies conducted by trained practitioners called Ngangas. Gabon legally protects iboga as a cultural heritage substance. Traditional ceremonial use differs significantly from Western clinical treatment models. Some treatment centers incorporate Bwiti-trained practitioners alongside medical staff.

Ibogaine Frequently Asked Questions